S. M. Ernst
13 Papers
1 Citations
S. M. Ernst is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 7 publications.
Chat about Author
Papers
Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
S. M. Ernst,Joanne Mankor,Job van Riet,Jan H. von der Thüsen,Hendrikus J. Dubbink,Joachim G.J.V. Aerts,Adrianus J. de Langen,Egbert F. Smit,Anne-Marie C. Dingemans,Kim Monkhorst +9 more
TL;DR: In this paper , the authors defined the classification of smoking-and nonsmoking-associated NSCLC on the basis of individual genomic tumor characteristics and could contribute to reducing the lung cancer stigma.
28
Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
Liesbeth M. Hondelink,S. M. Ernst,Peggy N. Atmodimedjo,Danielle Cohen,Janina L Wolf,Anne-Marie C. Dingemans,Hendrikus J. Dubbink,Jan H. von der Thüsen +7 more
TL;DR: In this paper , the authors performed unbiased testing of all cases, regardless of TNM stage, with targeted next-generation sequencing on 486 lung adenocarcinoma cases between 01- January 2014 and 01 February 2020.
15
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
A.A.M. Van der Veldt,Sjoukje F. Oosting,Rsn Fehrmann,Corine H. GeurtsvanKessel,Rob van Binnendijk,Anne-Marie C. Dingemans,Egbert F. Smit,T. Jeroen N. Hiltermann,Gerco den Hartog,M. Jalving,Tatjana T Westphal,Arkajyoti Bhattacharya,F. de Wilt,S. M. Ernst,Annemarie Boerma,L. van Zijl,Guus F. Rimmelzwaan,Pia Kvistborg,Cécile A. C. M. van Els,Nynke Y. Rots,Debbie van Baarle,John B. A. G. Haanen,Elisabeth G.E. de Vries +22 more
TL;DR: In the prospective multicenter VOICE trial as discussed by the authors , the seroconversion rate after two vaccinations with mRNA-1273 was not inferior in patients treated for solid tumors with immunotherapy (cohort B, n = 131), chemotherapy (colort C,n = 229), or chemoimmunotherapy (colhort D, n= 143).
2
Abstract 2137: Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib
S. M. Ernst,Ronald van Marion,Peggy N. Atmodimedjo,E. de Jonge,Ron H.J. Mathijssen,Marthe S. Paats,Peter de Bruijn,Ron H.N. van Schaik,Hendrikus J. Dubbink,Anne-Marie C. Dingemans +9 more
TL;DR: The CodeBreaK 200 trial showed that in patients with advanced KRAS G12C mutated (KRAS+) NSCLC sotorasib is superior to docetaxel for progression free survival (PFS) with a one-year PFS of 25% as discussed by the authors .
1
Journal Pre-proof Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
S. M. Ernst,Joanne Mankor,Job van Riet,Jan H. von der Thüsen,J Dubbink Hendrikus,Dubbink,Joachim G.J.V. Aerts,Adrianus J. de Langen,Egbert F. Smit,Anne-Marie,C. Dingemans,Kim Monkhorst +11 more
TL;DR: In this article , the authors defined the classification of smoking and non-smoking associated NSCLC based on individual genomic tumour characteristics and could contribute to reducing the lung cancer stigma by identifying mutational signatures associated with tobacco smoking, such as single base signature 4 (SBS4) and indel-based signature 3 (ID3).